Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liatermin · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Liatermin | EXPERIMENTAL | Bilateral continuous infusion of liatermin for up to 24 months. |
| Name | Type | Description |
|---|---|---|
| Liatermin | BIOLOGICAL | Liatermin |
| Liatermin (r-metHuGDNF) | DRUG | - |
Inclusion Criteria: - Completion of the 20020168 protocol
Liatermin is an investigational small molecule being developed for the treatment of Idiopathic Parkinson's Disease and Parkinson's Disease. It is administered by continuous intraputaminal infusion to patients with these conditions. Liatermin is currently in Phase 1 clinical development and is not approved by regulatory authorities.
Liatermin is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the safety and efficacy of Liatermin in patients with Parkinson's Disease.
Liatermin is in Phase 1 clinical development. It has completed one Phase 1 trial with 34 participants and is not yet approved for commercial use. The drug remains investigational and is being studied for the treatment of Parkinson's Disease.
Liatermin has been studied in two completed Phase 1 clinical trials: NCT00111982, which evaluated extended treatment with Liatermin in subjects with Idiopathic Parkinson's Disease who completed a previous trial, and NCT00115427, which studied Liatermin administered by bilateral intraputaminal infusion to subjects with Idiopathic Parkinson's Disease.
Liatermin is also known as r-metHuGDNF, as indicated in the clinical trial titles. The drug is being investigated under this alternative name in studies for Parkinson's Disease. Both names refer to the same investigational compound developed by Amgen.